Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study suggests that diffuse alopecia areata initially involves an intense inflammatory attack during the anagen phase, progressing through different hair cycle stages with specific shedding patterns.

In this observational study, researchers found that mini-pulse oral corticosteroids effectively reduced hair loss in alopecia areata patients who did not respond to topical therapies, though early-onset patients and those with hypothyroidism were less likely to benefit.

This research presents the Dodatek A model, elaborating on androgen function through new mathematical indices and methodological improvements, shifting focus from serum hormone concentrations to system interactions to better describe androgen activity comprehensively.

The authors of this meta-analysis suggest that intralesional injections of methotrexate and vitamin D3 may serve as safe and effective alternatives to triamcinolone acetonide for treating localized alopecia areata in adults, with trichoscopy aiding early detection of treatment effects.

This study found that alopecia areata patients had significantly abnormal T3, T4, TPOAbs, ANA, and lower vitamin D levels compared to healthy controls.

This study developed a new triamcinolone acetonide serum combined with a microneedling device, showing promise for treating alopecia areata by targeting hair follicles in a less invasive, patient-friendly way with confirmed drug solubility, compatibility, and safety.

Triamcinolone acetonide injections help regrow hair in alopecia areata patients.

This retrospective study found that oral tofacitinib significantly reduced the severity of alopecia areata in children, achieving over a 50% reduction in hair loss severity, though relapse occurred during treatment tapering, and mild adverse effects were noted.

This study found that oral tofacitinib at a 5mg twice daily dosage was effective in treating recalcitrant alopecia areata, showing significant improvement in hair regrowth and a 27% reduction in SALT scores over six months, with minimal side effects among the 19 patients monitored.

In this case study, treatment with the selective JAK1 inhibitor upadacitinib significantly improved symptoms in a patient with refractory alopecia areata, vitiligo, ankylosing spondylitis, and allergic asthma-nasal syndrome, though a transient liver function abnormality was noted.

Adalimumab significantly improves quality of life for patients with moderate to severe hidradenitis suppurativa.

This study found that nanobubble-encapsulated diclofenac with ultrasound-targeted microbubble destruction (DNBs-UTMD) can enhance the anti-tumor efficacy of Doxil® by regulating the tumor immune microenvironment, improving drug uptake, and increasing T cell responses while reducing immune-suppressive cells in the process.

Oral and topical tofacitinib can effectively treat severe hair loss with minimal side effects.

Men with Addison disease should be screened for X-linked adrenoleukodystrophy if they have hair loss.

This review found that Tolvaptan is the only drug shown to slow the progression of autosomal dominant polycystic kidney disease, but it does not affect mortality or kidney failure outcomes.

This study found that laboratory testing practices for alopecia areata vary among international hair experts, with the majority routinely conducting thyroid function and complete blood count tests, yet exhibiting diverse approaches toward testing for other conditions or before prescribing systemic therapy.

The document concludes that doctors should recognize congenital triangular alopecia to avoid unnecessary treatments, as it does not respond to steroids like alopecia areata does.

This study found that Tofacitinib effectively improved hair regrowth in patients with Alopecia Areata, with most participants showing a significant change in their Severity of Alopecia Tool scores.

Tavaborole is a safe and effective toenail fungus treatment, with the 5% solution being the best option.

This study evaluated the clinical outcomes of using tattoo equipment to deliver a combination of minoxidil and dutasteride directly to the scalp over three sessions for treating male androgenetic alopecia, but results are not reported in the abstract.

This case report describes a young girl with trichothiodystrophy and suggests the need for early diagnosis and multidisciplinary interventions for her educational challenges.

This report presents personal observations of alopecia areata in twins with autoimmune thyroiditis and suggests a possible link, though it does not provide new clinical results.

This study found that patients with alopecia areata have significantly higher medication adherence than those with atopic dermatitis, potentially due to the stability and controllability of alopecia areata symptoms.

This study found that AtT-20 pituitary cells with higher cAMP-dependent kinase activity had larger calcium currents and significantly increased beta-endorphin release compared to cells with lower kinase activity.

This study investigated alopecia areata in a mouse model, finding that tofacitinib may inhibit disease progression by modulating linoleic acid metabolism and magnesium pathways, particularly affecting CD8+ T cell infiltration in hair follicles, offering insights for potential treatments.

This study found that biallelic mutations in the TTC7A gene affect lymphocyte and gut epithelial cell function, thereby contributing to the development of inflammatory bowel disease in patients.

This review highlights the promising clinical outcomes of sacituzumab tirumotecan (sac-TMT), an antibody-drug conjugate for breast cancer that targets TROP2, demonstrating improved response rates and progression-free survival, with manageable safety concerns including primarily mild-to-moderate nausea and alopecia.

In this study, platelet-rich plasma significantly increased hair regrowth and reduced symptoms of alopecia areata compared to triamcinolone acetonide or placebo, with no observed side effects.

This study found that tofacitinib is an effective and more tolerable treatment than systemic corticosteroids for moderate-to-severe alopecia areata, and its combination with corticosteroids may offer improved efficacy.

This report documented a successful and sustained hair restoration surgery using follicular unit transplantation for temporal triangular alopecia, lasting over six years.